Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.60p
   
  • Change Today:
      0.000p
  • 52 Week High: 1.85
  • 52 Week Low: 0.55
  • Currency: UK Pounds
  • Shares Issued: 427.35m
  • Volume: 138,081
  • Market Cap: £2.56m
  • Beta: 0.95

Losses widen as Evgen Pharma develops SFX-01

By Josh White

Date: Monday 15 Jun 2020

LONDON (ShareCast) - (Sharecast News) - Clinical-stage drug development company Evgen Pharma reported a slight widening of its post-tax loss in its final results on Monday, to £2.7m, from £2.6m in the prior year.
The AIM-traded firm, which is pre-revenue, said its cash outflow from operations totalled £2.6m in the year ended 31 March, compared to £2.3m a year earlier.

Its cash balance at year-end stood at £4.1m, up from £2m year-on-year, after the company completed an oversubscribed fundraising in May 2019, which brought in £5m before expenses.

On the operational front, Evgen reported positive results from the STEM trial of 'SFX-01' in metastatic breast cancer, which was presented at the European Society of Medical Oncology Congress in Barcelona, demonstrating the stabilisation of previously-progressive disease and objective responses in some patients.

Five patients who participated in the STEM trial received SFX-01 treatment for more than one year, with no tumour progression.

Results from the 'SFX-01 After Subarachnoid Haemorrhage' (SAS) trial did not meet primary or secondary efficacy endpoints, although the treatment was well tolerated with no safety concerns, supporting evaluation in other indications.

Significant progress was made in tablet formulation of SFX-01, that would underpin easier clinical use in a range of indications and yield economic and production benefits.

Memorandums of understanding were reached with Guy's and St Thomas' NHS Foundation Trust, the University of Dundee and the University of Rochester in New York, to support clinical trials of SFX-01 in autism, non-alcoholic steatohepatitis and chronic kidney disease, respectively.

A research collaboration was also launched with King's College London and the British Heart Foundation, to investigate how SFX-01 mediates upregulation of Nrf2 in the blood-brain barrier endothelium in-vivo.

Since year-end, Evgen also noted the publication of preclinical data in Oncogene, for SFX-01's role in targeting STAT3 signalling and inhibition of endocrine resistant stem-like cells in ER-positive breast cancer.

"We move forward with the confidence that the value of SFX-01 as a potential drug that is active against the two key pathways of Nrf2 and STAT3 will become increasingly clear," said executive chairman Barry Clare.

"These pathways are of significance in a range of diseases including cancer, autism and those where oxidative stress is a factor.

"We therefore believe that the fundamentals are in place to underpin sustainable share price growth and deliver the undoubted potential of SFX-01."

At 0911 BST, shares in Evgen Pharma were down 16.67% at 9p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.60p
Change Today 0.000p
% Change 0.00 %
52 Week High 1.85
52 Week Low 0.55
Volume 138,081
Shares Issued 427.35m
Market Cap £2.56m
Beta 0.95

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
22.24% below the market average22.24% below the market average22.24% below the market average22.24% below the market average22.24% below the market average
68.00% above the sector average68.00% above the sector average68.00% above the sector average68.00% above the sector average68.00% above the sector average
Price Trend
82.93% below the market average82.93% below the market average82.93% below the market average82.93% below the market average82.93% below the market average
74.47% below the sector average74.47% below the sector average74.47% below the sector average74.47% below the sector average74.47% below the sector average
Income Not Available
Growth
17.39% below the market average17.39% below the market average17.39% below the market average17.39% below the market average17.39% below the market average
35.29% below the sector average35.29% below the sector average35.29% below the sector average35.29% below the sector average35.29% below the sector average

Theracryf Dividends

No dividends found

Trades for 12-Nov-2024

Time Volume / Share Price
15:40 101,522 @ 0.55p
12:58 36,559 @ 0.56p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page